Mesa Discusses What He’s Looking Forward to Most During 2022 in the Myelofibrosis Space

In 2022, we’re going to start to see some of these important phase 3 studies be reported out, and they’re going to be critically important. I’ve described it as if there’s multiple competing phase 3 clinical trials, what are those results and which patients benefit from which drug? How might we sequence them? How might we utilize them or compare them? I think this will become incredibly important. We will be considering what we anticipate with the use of a single-agent JAK2 inhibitors. Should everyone be on a combination? Should it be a subset or should we reverse switch to a second JAK2 inhibitor before we go to a combination? [There are many] questions. The data from the phase 3 studies are going to be incredibly important because although we have phase 2 data, they don’t really answer these questions. For the phase 3 data that are correlative studies, the long-term follow-up is going to be really important because we’ll have a range of options for treating folks. The differences that we learned from these data will help us make some of these decisions.